multiple-sclerosis

Documents about multiple-sclerosis

• Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy#862943ClinicalTrials.gov
• pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress#866537ClinicalTrials.gov
• Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis#879067ClinicalTrials.gov
• Pregnancy Cohort in Multiple Sclerosis (MS)#880018ClinicalTrials.gov
• Dalfampridine for Imbalance in Multiple Sclerosis#882643ClinicalTrials.gov
• Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.#884166ClinicalTrials.gov
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis#896949ClinicalTrials.gov
• Intervention for Employed Women With Multiple Sclerosis#906349ClinicalTrials.gov
• Natalizumab and Chronic Inflammation#908777ClinicalTrials.gov
• Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis#915054ClinicalTrials.gov
• PTNS for Female Patients Suffering From Multiple Sclerosis#966119ClinicalTrials.gov
• Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)#805737ClinicalTrials.gov
• A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)#850976ClinicalTrials.gov
• KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis#876724ClinicalTrials.gov
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors#910759ClinicalTrials.gov
• Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis#836747ClinicalTrials.gov
• Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM#837950ClinicalTrials.gov
• Effects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients#838675ClinicalTrials.gov
• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis#841224ClinicalTrials.gov
• Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis#855213ClinicalTrials.gov
• Current Exercise Approaches in Patients With Multiple Sclerosis#855900ClinicalTrials.gov
• Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis#857513ClinicalTrials.gov
• The HIt HArd and hiT Early in Multiple Sclerosis Trial#867538ClinicalTrials.gov
• The Therapeutic Effects of Forced Aerobic Exercise in Multiple Sclerosis#877912ClinicalTrials.gov
• Increasing Physical Activity for Adults With Multiple Sclerosis (MS)#879781ClinicalTrials.gov
• Auditory Function in Patients With and Without Multiple Sclerosis#880964ClinicalTrials.gov
• Caregiver Burden in Caregivers of Patients With Multiple Sclerosis#887900ClinicalTrials.gov
• Effect of Cooling on Balance Performance in Multiple Sclerosis#890092ClinicalTrials.gov
• Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis#892317ClinicalTrials.gov
• ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study#895968ClinicalTrials.gov
• Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis#896245ClinicalTrials.gov
• Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis#899264ClinicalTrials.gov
• Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers#899849ClinicalTrials.gov
• Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis#901069ClinicalTrials.gov
• Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)#904722ClinicalTrials.gov
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis#906990ClinicalTrials.gov
• MEsenchymal StEm Cells for Multiple Sclerosis#910612ClinicalTrials.gov
• Effect of the Vojta Therapy in Patients Multiple Sclerosis#918246ClinicalTrials.gov
• Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition#967299ClinicalTrials.gov
• Digital patient experience tools in multiple sclerosis: a landscape analysis of the global Patient-Reported Outcomes in Multiple Sclerosis (PROMS) initiative#5569Europe PMC
• A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia#850958ClinicalTrials.gov
• The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis#862041ClinicalTrials.gov
• Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis#915894ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis#968091ClinicalTrials.gov
• Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.#454280Dipòsit Digital de la Universitat de Barcelona
• A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis#897086ClinicalTrials.gov
• The Effect of Multiple-Task Training in Patients With Multiple Sclerosis#897926ClinicalTrials.gov
• Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients#899628ClinicalTrials.gov
• Towards a biologically informed description of multiple sclerosis disease course - a roadmap for transition#452170IRIS
• Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)#807483ClinicalTrials.gov